US.RVTY · Revvity

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 3.3890816259736862,
        "turnoverUsdM": 241.78831515000002,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.RVTY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 142.415,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 6.8,
      "take_profit_price": 161.054,
      "target_multiplier": 1.6,
      "technical_strength": 1.5,
      "take_profit_percent": 5.4
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.7781632519473725,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 79.4,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 54.4,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 25
  },
  "market": {
    "ma20": 137.687,
    "ma50": 125.4314,
    "close": 152.77,
    "prevClose": 151.02,
    "avgVolume20": 2191705,
    "volumeRatio": 0.72,
    "changePercent": 1.16
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 25,
    "details": {
      "ret_5d": 0.06601074593538492,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 25,
      "vcp_bonus": 0,
      "vol_ratio": 0.7213215991541182,
      "ret_points": 12,
      "vol_points": 0,
      "range_ratio": 0.6947894869639313,
      "volat_points": 0,
      "day_range_pct": 0.023859448844668577,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 8,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": true,
      "return_window_days": 5,
      "first_breakout_bonus": 2,
      "breakout_quality_points": 2
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 79.4,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.4,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 48,
        "contribution": 2.4
      },
      {
        "raw": 14,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 70,
        "contribution": 14
      },
      {
        "raw": 6.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 41.33,
        "contribution": 6.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.3,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 63,
        "contribution": 6.3
      },
      {
        "raw": 20.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 68.33,
        "contribution": 20.5
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 54.4,
    "details": [
      "基本面分析總分: 2.4/5分",
      "資金流分析總分: 14/20分",
      "市場環境分析總分: 6.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.3/10分",
      "技術信號分析總分: 20.5/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.4,
      "資金流": 14,
      "市場環境": 6.2,
      "情緒分析": 3,
      "技術信號": 20.5,
      "風險管理": 6.3
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 241.78831515000002,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 3.2,
          "obvPoints": 2.4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.RVTY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 722.9379963000001,
                "ma50": 714.3149974599999,
                "name": "QQQ",
                "close": 737.92999,
                "points": 2
              },
              "spy": {
                "ma20": 765.0209984,
                "ma50": 762.4543978399996,
                "name": "SPY",
                "close": 764.20001,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.3890816259736862,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142499577,
                "url": "https://finnhub.io/api/news?id=ff4832de7ba97e9983ed854de2a013c27c693bf0523e62c4715efc273d08445c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1790700002,
                "headline": "Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?"
              },
              {
                "id": 142423965,
                "url": "https://finnhub.io/api/news?id=a9ff4d3ba263b75cc7992bb9bb5763803e41a2e984ca6e0e139ac9d5b22bbd62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.",
                "category": "company",
                "datetime": 1790341740,
                "headline": "RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection"
              },
              {
                "id": 142350477,
                "url": "https://finnhub.io/api/news?id=cb58c8c8f2b541bcd7567cd8dc86f2dd0998a2a24d9e4da3258e8a9c57c37605",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) has drawn fresh attention after recent share price gains, with the stock up about 15% over the past month and roughly 36% over the past 3 months. Over the past year, Revvity has shifted from lagging long term returns, with a 5 year total shareholder return down 16.56%, to strong recent momentum. The 1 year total shareholder return reached 67.67%, and the 90 day share price return came in at 35.67%. Scan beyond Revvity's sharp rebound and explore other hand-picked opportunities...",
                "category": "company",
                "datetime": 1790129530,
                "headline": "Why Revvity (RVTY) Is Getting Attention Today"
              },
              {
                "id": 142188758,
                "url": "https://finnhub.io/api/news?id=03b1bbe1a346d39ced2120c20af628767c205f491c25a175a480c992424683c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1789550040,
                "headline": "Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?"
              },
              {
                "id": 142162217,
                "url": "https://finnhub.io/api/news?id=c9e230170d179b85b200d044ccc0f27596b9851ed1649e5e94f0dc70a6ee1f7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Revvity (NYSE:RVTY) and its peers.",
                "category": "company",
                "datetime": 1789479331,
                "headline": "Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks"
              },
              {
                "id": 142164499,
                "url": "https://finnhub.io/api/news?id=a187851a3b32d0f518cf6a22cdf7cb457662bd37fcebf1db3d2d732edf49b488",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "Revvity, Inc. (RVTY) 2026 Global Healthcare Conference September 15, 2026 9:05 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor...",
                "category": "company",
                "datetime": 1789473097,
                "headline": "Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript"
              },
              {
                "id": 142138505,
                "url": "https://finnhub.io/api/news?id=69174abc8d26e7ed40432acacd43de7ef7c90e09eac260583ae38c53c0592293",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1789385497,
                "headline": "Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 142026577,
                "url": "https://finnhub.io/api/news?id=cb092d0177c73ef991e01bd2f9b86bc6b770d0cc8355a7025df5d92b2dc0bbcc",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1788958626,
                "headline": "Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript"
              }
            ],
            "raw_source": [
              {
                "id": 142499577,
                "url": "https://finnhub.io/api/news?id=ff4832de7ba97e9983ed854de2a013c27c693bf0523e62c4715efc273d08445c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1790700002,
                "headline": "Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?"
              },
              {
                "id": 142498306,
                "url": "https://finnhub.io/api/news?id=b99b47066bf1db0d53f43dfd46ad34ae8002db612643d2fa307c56c3e05fdaf9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.",
                "category": "company",
                "datetime": 1790687520,
                "headline": "Here's Why You Should Retain Revvity Stock in Your Portfolio for Now"
              },
              {
                "id": 142463267,
                "url": "https://finnhub.io/api/news?id=fc9a13a952922c8e6a07e852b9dc7e22771cf21ad57968453bc3b6669662339b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
                "category": "company",
                "datetime": 1790586156,
                "headline": "1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds"
              },
              {
                "id": 142423965,
                "url": "https://finnhub.io/api/news?id=a9ff4d3ba263b75cc7992bb9bb5763803e41a2e984ca6e0e139ac9d5b22bbd62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.",
                "category": "company",
                "datetime": 1790341740,
                "headline": "RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection"
              },
              {
                "id": 142423581,
                "url": "https://finnhub.io/api/news?id=6c773b4b4fd56046165f9f939d6d09120e989435edcb977079470afccf6c629d",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Revvity (NYSE:RVTY) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below.\nThis content is powered by Benzinga APIs. For",
                "category": "company",
                "datetime": 1790313777,
                "headline": "Full Transcript: Revvity Q2 2026 Earnings Call"
              },
              {
                "id": 142385877,
                "url": "https://finnhub.io/api/news?id=0a10ab9058f099ea9dd8fed3a27d11f516b03ecf689b3ca7ecb544bfc4264f7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9",
                "category": "company",
                "datetime": 1790280084,
                "headline": "Sector Update: Healthcare Stocks Advance Late Afternoon"
              },
              {
                "id": 142385317,
                "url": "https://finnhub.io/api/news?id=f6f2a26b9f5647288b5da04eda91284fe1679478b8b585e97013ed1ba637efe8",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1790276701,
                "headline": "Discover which S&P500 stocks are making waves on Thursday."
              },
              {
                "id": 142423582,
                "url": "https://finnhub.io/api/news?id=dbcf2dda78e5857b21e4ffb41aceed01250ceb475132a6bb612a945f2768a415",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.72%. Currently, Revvity has a market capitalization of $16.82 billion.",
                "category": "company",
                "datetime": 1790271929,
                "headline": "Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years"
              },
              {
                "id": 142384739,
                "url": "https://finnhub.io/api/news?id=064fca65c12d5a6a144b02ffa288fa39c2b8d29421fbe717d8ae80b17cdacb6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "All three major US stock indexes fell in late-morning trading Thursday amid uncertainty in the Middl",
                "category": "company",
                "datetime": 1790265971,
                "headline": "Top Midday Stories: Oracle's Data Center Delay; People Withdraws MGM Offer; Revvity's New Diabetes Test"
              },
              {
                "id": 142374834,
                "url": "https://finnhub.io/api/news?id=57a218c79f8db9c5829dc0b25bcf5d3d5d2d104a3cb88128bac31f9d804f3aa9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., September 24, 2026--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear.",
                "category": "company",
                "datetime": 1790251200,
                "headline": "Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes"
              },
              {
                "id": 142379627,
                "url": "https://finnhub.io/api/news?id=6f5fae7103718fad61d71f792ffe7fcab9e945543672660195665d850dedefdd",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that",
                "category": "company",
                "datetime": 1790237027,
                "headline": "Revvity Rolls Out GSP T1D 3plex Kit"
              },
              {
                "id": 142363351,
                "url": "https://finnhub.io/api/news?id=08e21debb549e8d7bd2c4b8c5893e45852ed71ecc7711b290ef91bf21303ffcf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity has notably outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1790159593,
                "headline": "Is Revvity Stock Outperforming the Dow?"
              },
              {
                "id": 142350477,
                "url": "https://finnhub.io/api/news?id=cb58c8c8f2b541bcd7567cd8dc86f2dd0998a2a24d9e4da3258e8a9c57c37605",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) has drawn fresh attention after recent share price gains, with the stock up about 15% over the past month and roughly 36% over the past 3 months. Over the past year, Revvity has shifted from lagging long term returns, with a 5 year total shareholder return down 16.56%, to strong recent momentum. The 1 year total shareholder return reached 67.67%, and the 90 day share price return came in at 35.67%. Scan beyond Revvity's sharp rebound and explore other hand-picked opportunities...",
                "category": "company",
                "datetime": 1790129530,
                "headline": "Why Revvity (RVTY) Is Getting Attention Today"
              },
              {
                "id": 142328474,
                "url": "https://finnhub.io/api/news?id=85efb7d8043da2785c44589fe07e464369b52343ea3a62c863b956ea862cb220",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"Label-Free Detection - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Label-Free Detection was valued at US$553 Million in 2024 and is projected to reach US$847 Million by 2030, growing at a CAGR of 7.4",
                "category": "company",
                "datetime": 1790065560,
                "headline": "Capitalize on the Label-Free Detection Market Shift: Track How Danaher, Sartorius, Agilent, Bruker and Revvity Are Disrupting R&D ROI and Reshaping Global Revenue Through 2030"
              },
              {
                "id": 142328487,
                "url": "https://finnhub.io/api/news?id=293df837bbb17c71cf269b411ac0010b830920bae67dc70e20edcee04009550a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"High Content Screening (HCS) - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for High Content Screening (HCS) was valued at US$1.3 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing",
                "category": "company",
                "datetime": 1790065140,
                "headline": "Capitalize on High Content Screening Disruption: Decode How Thermo Fisher Scientific, Danaher, Revvity, and Yokogawa Are Reshaping Global R&D ROI and Revenue"
              },
              {
                "id": 142269870,
                "url": "https://finnhub.io/api/news?id=97da2091fb37a98868cc4df2c623e9c31db2fd3283341dda1e7fd6b0739faf09",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149954800/image_2149954800.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "U.S. stocks closed the week mixed as Treasury yields rose amid a Fed rate hike, and fears of AI development grew. Read more about this week's top events on Wall Street.",
                "category": "company",
                "datetime": 1789800247,
                "headline": "What Moved Markets This Week"
              },
              {
                "id": 142270772,
                "url": "https://finnhub.io/api/news?id=2fbac1a765a47bf212e99e40ad93c0b49a5ff423030f1a4db735d13f67e98fb2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/18/Diesel-Prices-Cross-6.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "The Fed hiked for the first time since 2023; the 10-year yield touched 5.04%, and record diesel prices hit truckers and automakers.",
                "category": "company",
                "datetime": 1789747909,
                "headline": "Fed Raises Rates, Yields Hit 2007 Highs as Fuel Costs Set Records: This Week On Wall Street"
              },
              {
                "id": 142249608,
                "url": "https://finnhub.io/api/news?id=713a37af216447ec3bd78a404d516aab7a7639f9e3cf8a77d99b3839d2ffcb44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.",
                "category": "company",
                "datetime": 1789719440,
                "headline": "1 Momentum  Stock with Promising Prospects and 2 Facing Headwinds"
              },
              {
                "id": 142198959,
                "url": "https://finnhub.io/api/news?id=568783958075196b65740530debea12cb32f6534984a1b55719ef4f7c7471b7c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1789585501,
                "headline": "Explore the top gainers and losers within the S&P500 index in today's session."
              },
              {
                "id": 142188758,
                "url": "https://finnhub.io/api/news?id=03b1bbe1a346d39ced2120c20af628767c205f491c25a175a480c992424683c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1789550040,
                "headline": "Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?"
              },
              {
                "id": 142167113,
                "url": "https://finnhub.io/api/news?id=b9533ba462e02bc4cdd69ebe009cce3b112c1338397a301218653d5b059ea426",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1789499101,
                "headline": "Discover which S&P500 stocks are making waves on Tuesday."
              },
              {
                "id": 142162217,
                "url": "https://finnhub.io/api/news?id=c9e230170d179b85b200d044ccc0f27596b9851ed1649e5e94f0dc70a6ee1f7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Revvity (NYSE:RVTY) and its peers.",
                "category": "company",
                "datetime": 1789479331,
                "headline": "Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks"
              },
              {
                "id": 142194774,
                "url": "https://finnhub.io/api/news?id=d1cab808ccf45cf13f1263e44cacc1adc587155103fca3659b6bbe4aa4db95f1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/15/Stock-Market-Graph-Crashing-Down--Wall-S.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.",
                "category": "company",
                "datetime": 1789478829,
                "headline": "10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today"
              },
              {
                "id": 142165183,
                "url": "https://finnhub.io/api/news?id=41ebfd4b80544d2c7c619a56a61cee031e3049ed69310da56b5dd1c7a7151515",
                "image": "https://image.cnbcfm.com/api/v1/image/108326254-1782318177071-gettyimages-2213364616-img_9901.jpeg?v=1782318352&w=1920&h=1080",
                "source": "CNBC",
                "related": "RVTY",
                "summary": "These are the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1789473808,
                "headline": "Stocks making the biggest moves midday: Skyworks Solutions, Axon, Dave & Buster's, Revvity & more"
              },
              {
                "id": 142164499,
                "url": "https://finnhub.io/api/news?id=a187851a3b32d0f518cf6a22cdf7cb457662bd37fcebf1db3d2d732edf49b488",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "Revvity, Inc. (RVTY) 2026 Global Healthcare Conference September 15, 2026 9:05 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor...",
                "category": "company",
                "datetime": 1789473097,
                "headline": "Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript"
              },
              {
                "id": 142195468,
                "url": "https://finnhub.io/api/news?id=84be75a7fa25fb4e6b70806a85064079868a4c59df9eb73aed8b3ebb3fbe2245",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical validation across Nu.Q NETs, Nu.Q Cancer, and Capture-Seq. Management has simultaneously decreased operating expenses, which were reduced in the most recent",
                "category": "company",
                "datetime": 1789402620,
                "headline": "VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space."
              },
              {
                "id": 142139504,
                "url": "https://finnhub.io/api/news?id=892ee473a89448e463e9ebabbdd3627fdd3c2e2cad825c716923497669bcd3f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.",
                "category": "company",
                "datetime": 1789399410,
                "headline": "3 Healthcare Stocks That Fall Short"
              },
              {
                "id": 142138505,
                "url": "https://finnhub.io/api/news?id=69174abc8d26e7ed40432acacd43de7ef7c90e09eac260583ae38c53c0592293",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1789385497,
                "headline": "Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 142087303,
                "url": "https://finnhub.io/api/news?id=ccd73376aab39d765a0ae9080eecae78d1cc12a45b23ff5dbdcee5c0d0633f93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.",
                "category": "company",
                "datetime": 1789139940,
                "headline": "Revvity to Acquire Human Cell Design to Boost Metabolic Discovery"
              },
              {
                "id": 142025419,
                "url": "https://finnhub.io/api/news?id=26ba77f1d5d5d1d933db3ca05680140c3536502285a122c8a8b36cdf9f7d1322",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Let's have a look at the S&P500 gap up and gap down stocks in today's session.",
                "category": "company",
                "datetime": 1788964501,
                "headline": "These S&P500 stocks are gapping in today's session"
              },
              {
                "id": 142026577,
                "url": "https://finnhub.io/api/news?id=cb092d0177c73ef991e01bd2f9b86bc6b770d0cc8355a7025df5d92b2dc0bbcc",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1788958626,
                "headline": "Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript"
              },
              {
                "id": 142007727,
                "url": "https://finnhub.io/api/news?id=c1105d1e4e608643a2f4b83f95153adcb96bcc32f5073d0146317266dabca956",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., September 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, includin",
                "category": "company",
                "datetime": 1788948000,
                "headline": "Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery"
              },
              {
                "id": 142026253,
                "url": "https://finnhub.io/api/news?id=14a165ee3da6cf1e87cced8f93e5010791421eec4a891b5f0776077838aedbf3",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "UBS  analyst Doug Schenkel   assumes Revvity (NYSE:RVTY) with a Neutral rating and raises Price Target to $140.",
                "category": "company",
                "datetime": 1788947825,
                "headline": "UBS Assumes Revvity at Neutral, Raises Price Target to $140"
              },
              {
                "id": 142026254,
                "url": "https://finnhub.io/api/news?id=afa5a4ecb2479e8eee511d8473093253608857e03a715a73a0bd02872012e9a4",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/09/Revvity-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Revvity buys Human Cell Design to expand diabetes and GLP-1 drug discovery tech. Acquisition expected to close in Q4 2026.",
                "category": "company",
                "datetime": 1788946529,
                "headline": "Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition"
              },
              {
                "id": 142026255,
                "url": "https://finnhub.io/api/news?id=c0e3abf1a20772b3a6ef5ac36a02a5c40065dd69d9c3e39cefaa9ae53e03f69c",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": " The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other",
                "category": "company",
                "datetime": 1788934162,
                "headline": "Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And Preclinical Research Solutions For Diabetes, Obesity And Other Metabolic Diseases"
              },
              {
                "id": 141950366,
                "url": "https://finnhub.io/api/news?id=9ffbefa46ae6a3e4ca32751051e8d41fdf4e5c7ea74772461a6e2e856ea0ded6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031\" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro",
                "category": "company",
                "datetime": 1788878940,
                "headline": "Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others"
              },
              {
                "id": 141425678,
                "url": "https://finnhub.io/api/news?id=f21a96053f253b59f417bd859feef95f766270d2e42bafa9937419d4bfaae0dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.",
                "category": "company",
                "datetime": 1788526140,
                "headline": "Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?"
              },
              {
                "id": 141420277,
                "url": "https://finnhub.io/api/news?id=8dff4283f6da452e92865d7101fd6ffa7f2bdc63d99febe33fac804fc18f8255",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher",
                "category": "company",
                "datetime": 1788518880,
                "headline": "Global Multiplex Assays Market 2026 Edition -  Consumables Dominate Multiplex Assays with 68% Market Share"
              },
              {
                "id": 141449917,
                "url": "https://finnhub.io/api/news?id=2f5b6dbf3c6e63d29e248fc2bc5f667c787cd9f592de5860faa835e287e2cc01",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Keybanc  analyst Paul Knight   maintains Revvity (NYSE:RVTY) with a Overweight and raises the price target from $125 to $165.",
                "category": "company",
                "datetime": 1788513490,
                "headline": "Keybanc Maintains Overweight on Revvity, Raises Price Target to $165"
              },
              {
                "id": 141394957,
                "url": "https://finnhub.io/api/news?id=c8b12fe4ed72ebc17bbb88c0ab2ddd6a474f4769bdf66b17e58abdee92cf8f1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based multiples point to a richer price. Revvity’s 57.5% 1 year return sets a high bar for new buyers, who now need the fundamentals to justify a much higher share price base. The key support for the current valuation can come from the company’s ability to convert...",
                "category": "company",
                "datetime": 1788401656,
                "headline": "Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings"
              },
              {
                "id": 141376585,
                "url": "https://finnhub.io/api/news?id=323914a6aab244c46436fbc5e705d5ab656e998a732346d572925b8e2cabe6fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) is back in focus after a recent Zacks upgrade to Rank #2, which reflects improved earnings expectations even as questions remain about growth momentum and rising competitive pressure. Over the past year Revvity’s share price return has been strong, with a 30 day share price return of 12.5%, a 90 day share price return of 25.25% and a year to date share price return of 28.98%, while the 1 year total shareholder return is 44.46%. This suggests that positive momentum has been...",
                "category": "company",
                "datetime": 1788350787,
                "headline": "Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade"
              },
              {
                "id": 141374543,
                "url": "https://finnhub.io/api/news?id=3c3b31f83fc72e07cc004c2544df885b3ea92baad1ce785e6334735ff53c1489",
                "image": "",
                "source": "Fintel",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1788331013,
                "headline": "RBC Capital Initiates Coverage of Revvity (RVTY) with Sector Perform Recommendation"
              },
              {
                "id": 141373643,
                "url": "https://finnhub.io/api/news?id=586a7b0273e63c068b81acc8775f2c6ac9290074de64940276220f0e54d8f76b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.",
                "category": "company",
                "datetime": 1788294620,
                "headline": "3 Hyped Up  Stocks We Find Risky"
              },
              {
                "id": 141370258,
                "url": "https://finnhub.io/api/news?id=6545bb751ae949e0c7ab96f599e32d8cc54b53cc4e6e0674e3f677f9ceef0bf7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
                "category": "company",
                "datetime": 1788282002,
                "headline": "What Makes Revvity (RVTY) a New Buy Stock"
              },
              {
                "id": 141370259,
                "url": "https://finnhub.io/api/news?id=b4010c5290b28cfc54157cb45359ef75b9687f7cc7d4fb5bcd195348a5cc80a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity's (RVTY) strong portfolio faces slowing growth and rising competition, raising questions abo",
                "category": "company",
                "datetime": 1788280978,
                "headline": "Revvity Faces Growth Challenges Amid Rising Competition, RBC Says"
              },
              {
                "id": 141370883,
                "url": "https://finnhub.io/api/news?id=da5596eb573a2739f70a4762282fc12f50cb2181b295291669cc4c0452c29761",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "RBC Capital  analyst Dan Leonard   initiates coverage on Revvity (NYSE:RVTY) with a Sector Perform rating and announces Price Target of $135.",
                "category": "company",
                "datetime": 1788249814,
                "headline": "RBC Capital Initiates Coverage On Revvity with Sector Perform Rating, Announces Price Target of $135"
              },
              {
                "id": 141361171,
                "url": "https://finnhub.io/api/news?id=40e9f3152f995605f71edc54cd5e8da04b68760f2b599ba43b23754aa3a6049b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "As UnitedHealth Group has outperformed relative to its industry peers over the past year, Wall Street analysts remain bullish about the stock’s prospects.",
                "category": "company",
                "datetime": 1788072487,
                "headline": "How Is UnitedHealth Group's Stock Performance Compared to Other Healthcare Plan Stocks?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.3,
            "source_article_count": 47,
            "discarded_article_count": 35
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.5,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.6,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.6,
            "vcp_reason": "波幅收縮(25.2%→15.4%)；站上MA50；升放量(近10日4日)；收盤突破20日高位；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 1967590,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 2633190,
              "avg_vol_20": 2194160,
              "avg_vol_30": 1967590,
              "range_pct_10": 0.15441506840348235,
              "range_pct_20": 0.20527583949728337,
              "range_pct_30": 0.252470969431171,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 4,
              "breakout_20d_ok": true,
              "vol_ratio_10_30": 1.3382818575008004,
              "dist_to_20d_high": -0.00334959958949178,
              "down_shrink_days": 1,
              "breakout_level_20d": 152.25999,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.611615144312975
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 1.6,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 3.3890816259736862,
              "turnoverUsdM": 241.78831515000002,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.RVTY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 142.415,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 6.8,
            "take_profit_price": 161.054,
            "target_multiplier": 1.6,
            "technical_strength": 1.5,
            "take_profit_percent": 5.4
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.7781632519473725,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.RVTY",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 5.1775,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.39
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 103.59
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1959
    },
    "kdj": {
      "d": 85.84,
      "j": 101.77,
      "k": 91.15,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 63.59
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 13878395,
      "recentSlope": 94119.5,
      "previousSlope": 453150
    },
    "rsi": 82.54,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 134.5906,
      "position": "SAR喺價下",
      "distancePct": 11.9,
      "previousTrend": "上升"
    },
    "ma50": 125.4314,
    "macd": {
      "macd": 7.619231332250848,
      "trend": "強烈看漲",
      "signal": 6.483359116858365,
      "histogram": 1.1358722153924834
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 138.2848,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 12
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.72,
      "score": 2,
      "avgVolume": 2191705,
      "currentVolume": 1582695
    },
    "derived": {
      "ma20": 137.687,
      "ma50": 125.4314,
      "prevClose": 151.02,
      "avgVolume10": 2422080,
      "avgVolume20": 2191705,
      "changePercent": 1.16,
      "avgVolumeForScore": 2191705
    },
    "ma_cross": {
      "ma20": 137.687,
      "ma50": 125.4314,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 136.482,
      "prevMa50": 124.5048,
      "spreadPct": 9.77,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 116.9582,
      "upper": 158.4158,
      "position": "上半部"
    },
    "rsi_short": 87.26,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.72
    }
  }
}

{
  "close": 152.77,
  "volume": 1582695,
  "changePercent": 1.16
}